Metagenomi Therapeutics, Inc. (MGX)

Metagenomi announced its corporate name change to Metagenomi Therapeutics, Inc. on January 12, 2026, highlighting the progress of MGX-001, which produced durable Factor VIII activity in non-human primates over approximately 19 months. The company anticipates submitting an IND/CTA in Q4 2026 and initiating first-in-human studies in 2027, with a projected cash runway into Q4 2027. Metagenomi announced it would present preclinical data supporting a new collaboration target of APOC3 with Ionis Pharmaceuticals at an upcoming Nature Conference on December 1, 2025. In November 2025, the company presented at the Jefferies Global Healthcare Conference in London and held an MGX-001 Program and Business Update Conference Call. In August 2024, Metagenomi reported business updates and second-quarter 2024 financial results, declaring MGX-001 as a development candidate for hemophilia A and planning to present 12-month NHP durability study data in September 2024. All Wave 1 Ionis collaboration programs were advancing, with potential for multiple development candidate nominations in 2025, and a milestone was achieved from partner Affini-T. The company also reported being well-capitalized with $299.9 million in cash, cash equivalents, and marketable securities at the end of Q2 2024, with a cash runway anticipated into 2027. In May 2025, the company reported additional long-term data from its nonhuman primate study, demonstrating durable and consistent FVIII activity levels through approximately 19 months.

The provided search results do not contain specific information about demand seasonality for Metagenomi Therapeutics, Inc.'s products and services; demand is likely driven by disease prevalence and clinical trial success rather than traditional seasonal patterns.

Metagenomi Therapeutics, Inc. is a precision genetic medicine company focused on developing curative therapeutics through its metagenomics-derived genome editing toolbox, with a core focus on in vivo gene editing. The company's toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems. Metagenomi's platform enables rapid discovery, screening, and selection of tools for genetic medicine development. The company's lead program, MGX-001, targets hemophilia A as a one-time curative treatment. Metagenomi has collaborations with ModernaTX, Inc., Ionis Pharmaceuticals, Inc., and Affini-T Therapeutics, Inc.

Metagenomi, Inc. is headquartered in Emeryville, California, United States, and develops therapeutics for patients using its metagenomics-derived genome editing toolbox in the United States.

The provided search results do not contain specific information about Metagenomi Therapeutics, Inc.'s brand reputation in the past year or any events that have specifically affected its reputation.

The provided search results do not contain specific details about major institutional and individual owners of Metagenomi Therapeutics, Inc.